Citable filing context
CAH's research view summarizes recent SEC filing context, starting with material_agreement from Oct 1, 2026.
| Filed | Item | Context |
|---|---|---|
| Oct 1, 2026 | material_agreement | Cardinal Health entered into a binding LOI to extend pharmaceutical distribution agreements with CVS Health through June 2032. |
| Aug 11, 2026 | debt_offering | Cardinal Health entered into a new $4.0 billion unsecured revolving credit facility expiring in 2031. |
| Aug 11, 2026 | earnings | Cardinal Health reported fourth quarter and fiscal year 2026 results and provided fiscal year 2027 guidance. |
| Oct 1, 2026 | Guidance: long_term_non_gaap_eps_growth | 12.00 to 14.00 |
| Oct 1, 2026 | Guidance: non_gaap_eps | 12.40 to 12.60 |
| Oct 1, 2026 | Guidance: non_gaap_eps_growth | 13.00 to 15.00 |
| Aug 11, 2026 | business | Cardinal Health is a global healthcare services and products company operating through three primary segments: Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and Other. The Pharmaceutical and Specialty Solutions segment, the company’s largest, distributes branded and generic pharmaceuticals and provides management services to physician practices through its Managed Service Organization (MSO) platforms, including The Specialty Alliance and Navista. The GMPD segment manufactures and sources Cardinal Health-branded medical, surgical, and laboratory products, while the Other segment encompasses at-Home solutions, nuclear pharmacy services, and logistics. Fiscal 2026 revenue reached $254.2 billion, a 14% increase driven by branded and specialty pharmaceutical sales. Non-GAAP operating earnings rose 30% to $3.6 billion, bolstered by MSO acquisitions and generic program performance. However, the company faces significant risks, including intense competition, high customer concentration—with CVS Health accounting for 28% of revenue—and a complex regulatory environment involving the DEA, FDA, and various anti-kickback statutes. The company is also navigating a volatile tariff landscape, including potential future tariffs on generic pharmaceuticals, and managing long-term opioid litigation settlements. Strategic focus remains on expanding specialty offerings through acquisitions, such as the $1.9 billion Solaris Health purchase, while managing debt and capital allocation. |
| Aug 11, 2026 | mda | Cardinal Health reported strong fiscal 2026 performance, with revenue increasing 14% to $254.2 billion, driven by branded and specialty pharmaceutical sales. Non-GAAP operating earnings rose 30% to $3.6 billion, bolstered by the performance of the Pharma segment’s generics program and the integration of Management Service Organization (MSO) platforms, specifically the $1.9 billion acquisition of Solaris Health. The Pharma segment remains the primary growth engine, though it faces headwinds from the Inflation Reduction Act’s drug price caps and potential future tariffs on generic pharmaceuticals. A notable operational challenge included a $184 million goodwill impairment charge related to the Navista & ION oncology unit, reflecting updated business model assumptions. The Global Medical Products and Distribution (GMPD) segment saw a 91% increase in segment profit, aided by the resolution of IEEPA tariff disputes, which resulted in a net benefit after customer repayments. Despite this, the company remains exposed to a volatile tariff environment across its global supply chain. Liquidity remains robust, with $4.9 billion in cash and equivalents. Capital deployment focused on MSO acquisitions, $1.4 billion in share repurchases, and ongoing payments related to national opioid litigation settlements, which are expected to continue through 2038. |
Source: SEC EDGAR filing text and events; period Oct 1, 2026; filed Oct 1, 2026.
CAH company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.